Join Now

Project Details
  • Title: Elucidating the Mechanism of the anti-angiogenic function of CDKN2A/p14ARF in Glioma
  • Date Proposed: 09/21/2009
  • Amount Requested: $200,000.00
  • Amount we Paid: $0.00
  • Paid Date: 01/01/2000
  • Stauts: Approved - Waiting For Funding
  • Research name: Erwin Van Meir
  • Hospital: Emory University
  • Grey Ribbon Crusade Participants:
    • Musella Foundation For Brain Tumor Research & Information, Inc
  • Simple Description: We hypothesize that ARF loss may be one of the genetic events that trigger angiogenesis dysregulation occurring during glioma formation. Accordingly, we aim to investigate ARF’s functions as p53-independent suppressor of tumor-induced angiogenesis and the mechanism underlying its activity. At the end of the proposed studies, we expect to have gained major insight into the molecular signaling mechanism by which ARF selectively inhibits tumor angiogenesis in gliomas. Such new signaling pathway will potentially reveal new targets that can be exploited for preventing tumor development and improving the therapeutic regimen that is currently applied to brain tumor patients. Request is for $100,000 a year for 2 years.